atenolol has been researched along with Complications of Diabetes Mellitus in 40 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A total of 9193 hypertensive patients (1195 with diabetes) in the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study were treated with losartan- or atenolol-based regimens and followed up with serial ECG and blood pressure determinations at baseline and 6 months and then yearly until death or study end." | 9.12 | Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Edelman, JM; Gerdts, E; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Lindholm, LH; Okin, PM; Snapinn, SM, 2006) |
| "The present post-hoc analyses were aimed at: describing the prevalence of the metabolic syndrome (MS) at baseline; investigating the effect of long-term antihypertensive therapy (and separately of atenolol and lacidipine) on MS prevalence; exploring whether MS at baseline influenced changes in carotid IMT and incidence of cardiovascular events during treatment; and describing the relations between MS and new cases of diabetes developing during treatment." | 9.12 | Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. ( Baurecht, H; Carugo, S; Cuspidi, C; Hennig, M; Mancia, G; Tang, R; Zanchetti, A, 2007) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study showed that treatment with the angiotensin II type-1 receptor antagonist losartan reduces overall stroke risk compared with conventional therapy with the beta-blocker atenolol." | 9.11 | Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Harris, KE; Ibsen, H; Julius, S; Kizer, JR; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wachtell, K; Wedel, H, 2005) |
| "As part of the LIFE study, in a double-masked, randomised, parallel-group trial, we assigned a group of 1195 patients with diabetes, hypertension, and signs of left-ventricular hypertrophy (LVH) on electrocardiograms losartan-based or atenolol-based treatment." | 9.10 | Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristiansson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2002) |
| "A 3-month double-blind multicenter trial compared the efficacy and safety of perindopril, a new angiotensin-converting enzyme (ACE) inhibitor, with atenolol in mild-to-moderate essential hypertension." | 9.07 | Antihypertensive efficacy and safety of perindopril in mild-to-moderate essential hypertension: results of a double-blind multicenter study versus atenolol. ( Anderson, AI; Bartholomeusz, LC; Cameron, DP; Conway, EL; Donnelly, T; Frewin, DB; Hooper, MJ; Louis, WJ; MacDonald, GJ; Morgan, TO, 1992) |
| "Six double-blind studies were designed to assess the efficacy, tolerance, and safety of the angiotensin-converting enzyme inhibitor ramipril in patients with mild-to-moderate essential hypertension." | 9.07 | Assessment of the efficacy, tolerance, and safety of ramipril in diabetic patients with mild-to-moderate hypertension: a retrospective analysis. ( Breitstadt, A; Erhard, W; Krall, H; Lindner, U; Pfeiffer, C, 1991) |
| "In a double-blind, randomized, cross-over study in 23 diabetic patients, insulin treated (N = 11) or noninsulin treated (N = 12), with mild to moderate hypertension, the hypotensive effects of captopril and atenolol were compared." | 9.06 | A comparison of the hypotensive effects of captopril and atenolol in the treatment of hypertension in diabetic patients. ( de Nobel, E; Elving, LD; Thien, T; van Lier, HJ, 1989) |
| "Losartan was very effective in reducing cardiovascular morbidity and mortality as compared to atenolol." | 6.71 | [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study]. ( Dahlöf, B; Ibsen, H; Kjeldsen, S; Lindholm, LH; Pedersen, OL, 2003) |
| "Electrocardiographic left ventricular hypertrophy (LVH) predicts cardiovascular morbidity and mortality, and regression of ECG LVH may predict improved prognosis in hypertensive patients." | 6.71 | Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. ( Aurup, P; Dahlof, B; Devereux, RB; Edelman, JM; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Nieminen, MS; Okin, PM; Snapinn, S, 2003) |
| "Losartan is an orally active, selective, nonpeptide, angiotensin-II Type I-receptor antagonist, and was the first drug marketed in this class." | 6.42 | Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Devereux, RB; Lyle, PA, 2004) |
| "A total of 9193 hypertensive patients (1195 with diabetes) in the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study were treated with losartan- or atenolol-based regimens and followed up with serial ECG and blood pressure determinations at baseline and 6 months and then yearly until death or study end." | 5.12 | Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Edelman, JM; Gerdts, E; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Lindholm, LH; Okin, PM; Snapinn, SM, 2006) |
| "Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 5.12 | The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study. ( Brady, WE; Dahlöf, B; Devereux, RB; Fossum, E; Gleim, GW; Hille, DA; Julius, S; Kizer, JR; Kjeldsen, SE; Lyle, PA, 2007) |
| "The present post-hoc analyses were aimed at: describing the prevalence of the metabolic syndrome (MS) at baseline; investigating the effect of long-term antihypertensive therapy (and separately of atenolol and lacidipine) on MS prevalence; exploring whether MS at baseline influenced changes in carotid IMT and incidence of cardiovascular events during treatment; and describing the relations between MS and new cases of diabetes developing during treatment." | 5.12 | Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. ( Baurecht, H; Carugo, S; Cuspidi, C; Hennig, M; Mancia, G; Tang, R; Zanchetti, A, 2007) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study showed that treatment with the angiotensin II type-1 receptor antagonist losartan reduces overall stroke risk compared with conventional therapy with the beta-blocker atenolol." | 5.11 | Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Harris, KE; Ibsen, H; Julius, S; Kizer, JR; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wachtell, K; Wedel, H, 2005) |
| "To compare efficacy and safety of atenolol, methoprolol and bisoprolol, as the most usable beta-blockers, in patients with isolated systolic arterial hypertension (ISAH) and concomitant diabetes mellitus (DM) and/or chronic obstructive pulmonary disease (COPD)." | 5.10 | [Efficacy and safety of different beta-blockers in patients with isolated systolic hypertension associated with diabetes mellitus and obstructive pulmonary diseases]. ( Abakumov, IuE; Batutina, AM; Kukes, VG; Mamaev, VI; Ostroumova, OD; Zykova, AA, 2003) |
| "As part of the LIFE study, in a double-masked, randomised, parallel-group trial, we assigned a group of 1195 patients with diabetes, hypertension, and signs of left-ventricular hypertrophy (LVH) on electrocardiograms losartan-based or atenolol-based treatment." | 5.10 | Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristiansson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2002) |
| "A 3-month double-blind multicenter trial compared the efficacy and safety of perindopril, a new angiotensin-converting enzyme (ACE) inhibitor, with atenolol in mild-to-moderate essential hypertension." | 5.07 | Antihypertensive efficacy and safety of perindopril in mild-to-moderate essential hypertension: results of a double-blind multicenter study versus atenolol. ( Anderson, AI; Bartholomeusz, LC; Cameron, DP; Conway, EL; Donnelly, T; Frewin, DB; Hooper, MJ; Louis, WJ; MacDonald, GJ; Morgan, TO, 1992) |
| "Six double-blind studies were designed to assess the efficacy, tolerance, and safety of the angiotensin-converting enzyme inhibitor ramipril in patients with mild-to-moderate essential hypertension." | 5.07 | Assessment of the efficacy, tolerance, and safety of ramipril in diabetic patients with mild-to-moderate hypertension: a retrospective analysis. ( Breitstadt, A; Erhard, W; Krall, H; Lindner, U; Pfeiffer, C, 1991) |
| "In a double-blind, randomized, cross-over study in 23 diabetic patients, insulin treated (N = 11) or noninsulin treated (N = 12), with mild to moderate hypertension, the hypotensive effects of captopril and atenolol were compared." | 5.06 | A comparison of the hypotensive effects of captopril and atenolol in the treatment of hypertension in diabetic patients. ( de Nobel, E; Elving, LD; Thien, T; van Lier, HJ, 1989) |
| "The recent Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study was conducted in patients with essential hypertension with electrocardiogram evidence of left ventricular hypertrophy." | 4.82 | Implications of the LIFE trial. ( Lim, HS; Lip, GY; Nadar, S, 2003) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, a major reduction of all-cause mortality--especially cardiovascular mortality--in patients with diabetes with left ventricular hypertrophy was reported for treatment with losartan." | 3.72 | Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Edelman, JM; Ibsen, H; Lindholm, LH; Olsen, MH; Snapinn, S; Wachtell, K, 2003) |
| "Losartan was very effective in reducing cardiovascular morbidity and mortality as compared to atenolol." | 2.71 | [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study]. ( Dahlöf, B; Ibsen, H; Kjeldsen, S; Lindholm, LH; Pedersen, OL, 2003) |
| "Electrocardiographic left ventricular hypertrophy (LVH) predicts cardiovascular morbidity and mortality, and regression of ECG LVH may predict improved prognosis in hypertensive patients." | 2.71 | Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. ( Aurup, P; Dahlof, B; Devereux, RB; Edelman, JM; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Nieminen, MS; Okin, PM; Snapinn, S, 2003) |
| "Atenolol or enalapril was the mandatory second-line drug." | 2.69 | Influence of diabetes and type of hypertension on response to antihypertensive treatment. ( Brown, MJ; Castaigne, A; de Leeuw, PW; Mancia, G; Palmer, CR; Rosenthal, T; Ruilope, LM, 2000) |
| "Atenolol treatment significantly increased triglyceride levels and decreased the HDL-cholesterol levels after 9 months in both groups." | 2.68 | Comparative effects of atenolol versus nifedipine on serum lipids and other biochemical parameters in diabetic and non-diabetic hypertensive subjects. ( Goyal, RK; Satia, MC; Shukla, ML, 1995) |
| "Losartan is an orally active, selective, nonpeptide, angiotensin-II Type I-receptor antagonist, and was the first drug marketed in this class." | 2.42 | Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Devereux, RB; Lyle, PA, 2004) |
| "Metoprolol treatment produced a slight but significant reduction in serum glucose levels with elevation in serum insulin levels, while atenolol produced a slight increase in glucose levels but no effect on insulin levels." | 1.34 | Comparative evaluation of atenolol and metoprolol on cardiovascular complications associated with streptozotocin-induced diabetic rats. ( Bhadada, SV; Goyal, RK, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (15.00) | 18.7374 |
| 1990's | 5 (12.50) | 18.2507 |
| 2000's | 27 (67.50) | 29.6817 |
| 2010's | 2 (5.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaomongkolgit, R | 1 |
| Ganz, PA | 1 |
| Cole, SW | 1 |
| Malik, RA | 1 |
| Karpov, IuA | 1 |
| Ibsen, H | 5 |
| Lindholm, LH | 6 |
| Pedersen, OL | 1 |
| Dahlöf, B | 8 |
| Kjeldsen, S | 1 |
| Nadar, S | 1 |
| Lim, HS | 1 |
| Lip, GY | 1 |
| Okin, PM | 2 |
| Devereux, RB | 7 |
| Jern, S | 2 |
| Kjeldsen, SE | 6 |
| Julius, S | 6 |
| Nieminen, MS | 4 |
| Snapinn, S | 3 |
| Harris, KE | 3 |
| Aurup, P | 2 |
| Edelman, JM | 4 |
| Oganov, RG | 1 |
| Lepakhin, VK | 1 |
| Fitilev, SB | 1 |
| Levin, AM | 1 |
| Titarova, YY | 1 |
| Sytchev, EN | 1 |
| Borch-Johnsen, K | 1 |
| Olsen, MH | 1 |
| Wachtell, K | 2 |
| Baumgart, P | 2 |
| Diener, HC | 1 |
| Kukes, VG | 1 |
| Ostroumova, OD | 1 |
| Mamaev, VI | 1 |
| Batutina, AM | 1 |
| Abakumov, IuE | 1 |
| Zykova, AA | 1 |
| Bakris, GL | 1 |
| Gaxiola, E | 1 |
| Messerli, FH | 1 |
| Mancia, G | 3 |
| Erdine, S | 1 |
| Cooper-DeHoff, R | 1 |
| Pepine, CJ | 1 |
| Lyle, PA | 2 |
| Kizer, JR | 2 |
| Beevers, G | 3 |
| de Faire, U | 3 |
| Fyhrquist, F | 3 |
| Kristianson, K | 1 |
| Lederballe-Pedersen, O | 3 |
| Omvik, P | 3 |
| Oparil, S | 3 |
| Wedel, H | 3 |
| Snapinn, SM | 2 |
| Gerdts, E | 1 |
| Coleman, JJ | 1 |
| Kendall, MJ | 1 |
| Sankar, D | 1 |
| Rao, MR | 1 |
| Sambandam, G | 1 |
| Pugalendi, KV | 1 |
| Fossum, E | 1 |
| Gleim, GW | 1 |
| Brady, WE | 1 |
| Hille, DA | 1 |
| Bhadada, SV | 1 |
| Goyal, RK | 2 |
| Zanchetti, A | 1 |
| Hennig, M | 1 |
| Baurecht, H | 1 |
| Tang, R | 1 |
| Cuspidi, C | 1 |
| Carugo, S | 1 |
| Maiorano, G | 1 |
| Loiacono, N | 1 |
| Castelnuovo, F | 1 |
| Altomare, E | 1 |
| Di Bello, V | 1 |
| Albano, O | 1 |
| Satia, MC | 1 |
| Shukla, ML | 1 |
| Leung, JM | 1 |
| Robles, NR | 1 |
| Martin, ME | 1 |
| Brown, MJ | 1 |
| Castaigne, A | 1 |
| de Leeuw, PW | 1 |
| Palmer, CR | 1 |
| Rosenthal, T | 1 |
| Ruilope, LM | 1 |
| Levinson, PD | 1 |
| Bory, M | 1 |
| Kristiansson, K | 2 |
| Edelman, J | 1 |
| Deacon, SP | 1 |
| Karunanayake, A | 1 |
| Barnett, D | 1 |
| Morgan, TO | 1 |
| Louis, WJ | 1 |
| MacDonald, GJ | 1 |
| Conway, EL | 1 |
| Bartholomeusz, LC | 1 |
| Anderson, AI | 1 |
| Cameron, DP | 1 |
| Donnelly, T | 1 |
| Frewin, DB | 1 |
| Hooper, MJ | 1 |
| Erhard, W | 1 |
| Lindner, U | 1 |
| Krall, H | 1 |
| Breitstadt, A | 1 |
| Pfeiffer, C | 1 |
| Elving, LD | 1 |
| de Nobel, E | 1 |
| van Lier, HJ | 1 |
| Thien, T | 1 |
| Opie, LH | 1 |
| Kwan, CM | 2 |
| Shepherd, AM | 2 |
| Johnson, J | 2 |
| Taylor, WF | 2 |
| Brockway, BA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| Angiotensin Blocking Effect of Fimasartan on Hypertensive Cardiac Disease With Left Ventricular Hypertrophy Estimated by ECG: a Prospective, Multicenter, Observational Registry[NCT03219632] | 72 participants (Actual) | Observational [Patient Registry] | 2012-06-05 | Completed | |||
| INternational VErapamil SR Trandolapril STudy[NCT00133692] | Phase 4 | 22,000 participants | Interventional | 1997-09-30 | Completed | ||
| Improving Outcomes in Atrial Fibrillation Patients Aided by Implantable Cardiac Monitor: Evaluation of Chronic Beta-blocker Use Versus As-needed Pharmacological Rate Control[NCT05745337] | Phase 1 | 20 participants (Anticipated) | Interventional | 2023-02-06 | Recruiting | ||
| Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol[NCT02403349] | Phase 4 | 105 participants (Actual) | Interventional | 2012-05-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for atenolol and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
[Clinical hypertensiology: analysis of trials completed in 2001-2002].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2002 |
Implications of the LIFE trial.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; At | 2003 |
Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2004 |
The Anglo-Scandinavian Cardiac Outcomes Trial-- blood pressure lowering arm.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Blockers | 2006 |
Beta-blockers, diabetes, and hypoglycemia: risky business?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 2001 |
[Does diabetes change the anti-ischemic therapeutic options in the symptomatic coronary patient?].
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Antihypertensive Agents; Atenolol; Como | 2000 |
18 trials available for atenolol and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Prevention of cardiovascular morbidity with angiotension receptor blockade: life after LIFE.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Atenolol; Clinical Pr | 2002 |
[The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study].
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diabe | 2003 |
Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Dia | 2003 |
Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Dia | 2003 |
Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Dia | 2003 |
Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Dia | 2003 |
[Efficacy and safety of different beta-blockers in patients with isolated systolic hypertension associated with diabetes mellitus and obstructive pulmonary diseases].
Topics: Adrenergic beta-Antagonists; Atenolol; Bisoprolol; Blood Pressure; Blood Pressure Monitoring, Ambula | 2003 |
Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; | 2005 |
Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Complications; Diabetes Mellitu | 2006 |
The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diabetes Compli | 2007 |
Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness.
Topics: Aged; Antihypertensive Agents; Atenolol; Atherosclerosis; Calcium Channel Blockers; Carotid Arteries | 2007 |
Comparative effects of atenolol versus nifedipine on serum lipids and other biochemical parameters in diabetic and non-diabetic hypertensive subjects.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Glucose; Blood Pressure; Blood Urea Nitrogen; Creatin | 1995 |
Influence of diabetes and type of hypertension on response to antihypertensive treatment.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Blockers | 2000 |
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetics.
Topics: Acebutolol; Adolescent; Adult; Atenolol; Blood Glucose; Clinical Trials as Topic; Diabetes Complicat | 1977 |
Antihypertensive efficacy and safety of perindopril in mild-to-moderate essential hypertension: results of a double-blind multicenter study versus atenolol.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Atenolol; C | 1992 |
Assessment of the efficacy, tolerance, and safety of ramipril in diabetic patients with mild-to-moderate hypertension: a retrospective analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensi | 1991 |
A comparison of the hypotensive effects of captopril and atenolol in the treatment of hypertension in diabetic patients.
Topics: Adult; Aged; Atenolol; Blood Glucose; Blood Pressure; Captopril; Clinical Trials as Topic; Diabetes | 1989 |
Forearm and finger hemodynamics, blood pressure control, and lipid changes in diabetic hypertensive patients treated with atenolol and prazosin. A brief report.
Topics: Adult; Aged; Atenolol; Blood Pressure; Diabetes Complications; Diabetes Mellitus; Female; Fingers; F | 1989 |
Forearm and finger hemodynamics, blood pressure control, and lipid changes in patients with diabetic hypertension treated with atenolol and prazosin.
Topics: Adult; Aged; Atenolol; Blood Pressure; Clinical Trials as Topic; Diabetes Complications; Female; Fin | 1988 |
16 other studies available for atenolol and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Oral lichenoid drug reaction associated with antihypertensive and hypoglycemic drugs.
Topics: Antihypertensive Agents; Atenolol; Chlorpropamide; Diabetes Complications; Diabetes Mellitus; Erythe | 2010 |
Expanding our therapeutic options: Beta blockers for breast cancer?
Topics: Adrenergic beta-Antagonists; Atenolol; Breast Neoplasms; Diabetes Complications; Disease-Free Surviv | 2011 |
No morbidity-mortality. Commentary.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II; Angiotensin Receptor Antagonists; Atenolol; Diabe | 2002 |
[Diagnosis and therapy of stable angina in Russian Federation (International Study ATP - angina treatment pattern)].
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; Angina Pectoris; Angiotens | 2003 |
Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study.
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Comorbidity; Dea | 2003 |
[LIFE study proves preventive action. With losartan to do even more against stroke].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Co | 2003 |
[Primary prevention of stroke. What helps--what does not help? The guidelines of the German Society of Neurology briefly summarized].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Alcohol Drinking; Anticholesteremic | 2003 |
Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 2004 |
A pilot study of open label sesame oil in hypertensive diabetics.
Topics: Aged; Antihypertensive Agents; Antioxidants; Atenolol; Blood Glucose; Body Mass Index; Diabetes Comp | 2006 |
Comparative evaluation of atenolol and metoprolol on cardiovascular complications associated with streptozotocin-induced diabetic rats.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Blood Glucose; Blood Pressure; Cardiomegaly; Cardiov | 2007 |
[Fewer cases of stroke, atrial fibrillation, diabetes and renal insufficiency. Good treatment of hypertension is more than lowering of blood pressure].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2008 |
[Carbohydrate metabolism and beta-blocking agents: effects of atenolol therapy].
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Glucose; Carbohydrate Metabolism; Diabetes Compl | 1981 |
Diabetes and not lack of treatment with atenolol predicts decreased survival after noncardiac surgery.
Topics: Adrenergic beta-Antagonists; Atenolol; Cardiovascular Diseases; Diabetes Complications; Humans | 1999 |
[New central agents in the treatment of arterial hypertension].
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adrenergic Uptake Inhibitors; Adult; Antihyp | 1999 |
Hypertension in the elderly.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin Receptor Antagonists; Angiotensin-Conver | 2000 |
Qualities of an ideal beta-adrenoceptor antagonist and comparison of existing agents with a new cardioselective hydrophilic vasodilator beta-adrenoceptor antagonist, celiprolol.
Topics: Adrenergic beta-Antagonists; Airway Resistance; Antihypertensive Agents; Atenolol; Celiprolol; Diabe | 1988 |